On January 4, 2021 Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 5:20 p.m. ET (Press release, Scholar Rock, JAN 4, 2021, View Source [SID1234573431]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at View Source An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.

On January 4, 2021 Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, reported that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021, at 11:30 a.m. Eastern time (Press release, Castle Biosciences, JAN 4, 2021, View Source [SID1234573429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at View Source A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

On January 4, 2021 Repare Therapeutics, Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, reported that Lloyd M. Segal, President and Chief Executive Officer, will present at two upcoming virtual investor conferences (Press release, Repare Therapeutics, JAN 4, 2021, View Source [SID1234573428]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Virtual BioConnect Conference
Date: Monday, January 11 – Thursday, January 14

39th Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 14
Time: 8:20 a.m. Eastern Time

The H.C. Wainwright presentation will be pre-recorded and available on Monday, January 11, 2021, at 6:00 a.m. Eastern Time in the Investor section of the Company’s website at View Source A live webcast of the J.P. Morgan presentation will be available in the same section of the website. A replay of both webcasts will be archived for 30 days following each presentation date.

On January 4, 2021 BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, reported that Jonathan Solomon, Chief Executive Officer, will participate in the following upcoming investor conferences (Press release, BiomX, JAN 4, 2021, View Source [SID1234573427]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright BioConnect Conference
Dates: January 11-14, 2021
Time: Playback available 6 a.m. EST January 11
Webcast link: BiomX – HCW BioConnect Conference Playback
The webcast will also be available in the Events section of the BiomX website at www.biomx.com.

Event: Oppenheimer Virtual Banking Meeting
Dates: January 11-14, 2021
1×1 meetings only

On January 4, 2021 DURECT Corporation (Nasdaq: DRRX) reported that the sale of the LACTEL product line to Evonik closed and the $15 million payment was received on December 31, 2020 (Press release, DURECT, JAN 4, 2021, https://investors.durect.com/news-releases/news-release-details/durect-corporation-announces-closing-lactelr-absorbable-polymer?field_nir_news_date_value[min]=2021 [SID1234573426]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!